Agendia to Participate in the 39th Annual J.P. Morgan Healthcare Conference
IRVINE, Calif.--(BUSINESS WIRE)--Agendia, Inc., a world leader in precision oncology Read More
Updated Outcome and Treatment Benefit Data from MINDACT Study Reinforce Real-World Value of MammaPrint for Clinical Low Risk Breast Cancer Patients at SABCS 2020
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – December 11, 2020 Read More
Agendia Spotlight Poster at SABCS 2020 Confirms Pre-Operative Utility of MammaPrint and BluePrint
Clinical utility of molecular subtyping and risk of recurrence profiling Read More
Results from APHINITY Trial using BluePrint as a Biomarker Assay Presented at SABCS in Poster Spotlight Discussion
Agendia and Roche evaluate BluePrint’s stratification of HER2+ early breast Read More
Agendia Presents Broad Spectrum of Data from FLEX Study Highlighting Tumor Heterogeneity within Underrepresented or Underserved Patient Populations at SABCS 2020
Agendia shares subgroup analyses from the first of its kind, Read More
FOCUS Study Shows MammaPrint Accurately Identifies Extremely Indolent Cancers
Findings confirm subanalysis of STO-3 trial and provide foundation for Read More
Agendia and Paige Announce Landmark Strategic Partnership to Revolutionize Treatment Planning in Breast Cancer
Co-development program will utilize next-generation digital pathology platform and AI-based Read More
Agendia to Showcase Robust Clinical Research at SABCS 2020 Emphasizing Need for Diversity of Data to Treat Breast Cancer Patients
Variety of data confirm the importance of applying genomic analysis Read More
Agendia to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference
IRVINE, Calif.--(BUSINESS WIRE)--Agendia, Inc., a world leader in precision oncology Read More
Agendia Co-Founder Named to Eighth Annual OncLive® Giants of Cancer Care® Class of Inductees
Laura van ’t Veer among 15 trailblazers in oncology honored Read More